Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.72 EUR
Change Today +0.006 / 0.84%
Volume 0.0
TN7 On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 1:37 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

titan pharmaceuticals inc (TN7) Snapshot

Open
€0.71
Previous Close
€0.72
Day High
€0.73
Day Low
€0.71
52 Week High
05/21/15 - €0.73
52 Week Low
11/19/14 - €0.29
Market Cap
79.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
110.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TITAN PHARMACEUTICALS INC (TN7)

titan pharmaceuticals inc (TN7) Related Businessweek News

No Related Businessweek News Found

titan pharmaceuticals inc (TN7) Details

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company is developing Probuphine for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment; and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company’s ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease. It is also developing Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

13 Employees
Last Reported Date: 03/31/15
Founded in 1992

titan pharmaceuticals inc (TN7) Top Compensated Officers

Principal Executive Officer, President, Princ...
Total Annual Compensation: $300.0K
Executive Chairman and Member of Executive Co...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2014.

titan pharmaceuticals inc (TN7) Key Developments

Titan Pharmaceuticals Inc. Announces Earnings Results for the First Quarter of 2015

Titan Pharmaceuticals Inc. announced earnings results for the first quarter of 2015. For the quarter, the company reported total revenues in the first quarter of 2015 and 2014 were consistent at about $0.9 million. The first quarter revenues consisted entirely of license revenue and reflect the amortization of the upfront license fee received from development and commercialization partner, Braeburn Pharmaceuticals in December 2012. Net loss for the first quarter 2015 was about $4.9 million or about $0.04 per share compared with about $1.8 million or about $0.02 per share in the same quarter in 2014.

Titan Pharmaceuticals Inc. to Report Q1, 2015 Results on May 14, 2015

Titan Pharmaceuticals Inc. announced that they will report Q1, 2015 results at 1:00 PM, Eastern Daylight on May 14, 2015

Titan Pharmaceuticals Inc., Q1 2015 Earnings Call, May 14, 2015

Titan Pharmaceuticals Inc., Q1 2015 Earnings Call, May 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TN7:GR €0.72 EUR +0.006

TN7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $59.92 USD -0.65
Reckitt Benckiser Group PLC 5,911 GBp -6.00
View Industry Companies
 

Industry Analysis

TN7

Industry Average

Valuation TN7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.3x
Price/Book 20.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TITAN PHARMACEUTICALS INC, please visit www.titanpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.